Verona to study RPL554 in Phase IIb trial for COPD in five European countries

UK-based biopharmaceutical firm Verona Pharma has secured regulatory approval to start a Phase IIb clinical trial of RPL554 in patients with chronic obstructive pulmonary disease (COPD) in the UK, Germany, Romania, Bulgaria and the Czech Republic.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news